RYNZN, another possibility for the report is to potentially assist in providing any takeover defence. By this i mean there maybe lowball offers made, which can easily be "batted" away by pointing to external analyst valuations. As a rule of thumb, a premium of 30% to 50% should be added to the higher of a 7 day/28 day VWAP price or "independent valuation averages". This report would be classified as an independent valuation. The above premium ranges are generally for businesses who produce EBITDA and are well established. I'm not an expert on premiums for Biotechs in Phase 2 or Phase 3, but I am reliably informed, depending upon prior results, safety etc, that they are much higher. In the hundreds of percent. Anyway, even if this wasn't a reason for the commissioning of the report, it may prove to be a valuable tool in the short term future.....
- Forums
- Charts
- Chart
RYNZN, another possibility for the report is to potentially...
-
- There are more pages in this discussion • 3,609 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.3¢ | 8.4¢ | 8.0¢ | $99.06K | 1.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 40625 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 0.078 |
1 | 10000 | 0.077 |
1 | 180000 | 0.076 |
4 | 186800 | 0.075 |
3 | 180866 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 40625 | 1 |
0.084 | 120000 | 1 |
0.085 | 363000 | 2 |
0.086 | 480000 | 3 |
0.087 | 400000 | 1 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |